Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 20, 2018
Pharmacy Choice - News - Generic Drugs - January 20, 2018

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 64     Next >>     Go To Page:

1/20/18 - Cadila Healthcare`s Dabhasa plant clears USFDA inspection [Algeria Press Service]
Cadila Healthcare reported that its Dabhasa plant has cleared a USFDA audit with zero observations. Cadila Healthcare is currently trading at Rs447.15, up by Rs11.05 or 2.53% from its previous closing of Rs436.1 on the BSE. Cadila Healthcare is a fully-integrated, pharmaceutical company with strong presence in the formulations and CRAMS businesses.
1/20/18 - EC approves biosimilar bevacizumab for the treatment of certain types of cancer [Arab News (Saudi Arabia)]
Amgen and Allergan plc have that the European Commission has granted marketing authorisation for MVASI. The European Commissions approval of MVASI marks a significant milestone for both Amgen and the oncology community, providing a biosimilar for a medicine which is used across multiple types of cancer, said Sean E Harper, MD, executive vice presid
1/20/18 - Japanese firms eye Asia factories for generic drugs [Arab Finance (Egypt)]
The Japanese government is planning new measures to help Japanese companies construct pharmaceutical factories in Asian countries, where labour costs are lower than in Japan, to encourage the production of more generic drugs. The Headquarters for Healthcare and Medical Strategy Promotion chaired by Prime Minister Shinzo Abe is proceeding with the s
1/20/18 - Not-for-profit hospitals coming up with their own generic medicines to combat shortages [Sudan Tribune]
Many of the major not-for-profit hospital groups have tried their hand an manufacturing and making generics to combat the shortages of medicines as well as the high costs of branded medications. This move bypasses the monopoly held by the pharmaceutical companies. Hospital groups that are joining hands in this venture include Intermountain Health,.
1/20/18 - Novartis doubles down on biosimilars with Biocon alliance [Sudan Tribune]
The deal with Novartis` subsidiary Sandoz comes after Biocon resolved problems at its manufacturing facility that forced it to withdraw EU filings for biosimilar versions of Roche`s breast cancer drug Herceptin and Amgen`s long-acting white cell booster Neulasta last August at the request of the EMA. The companies will share responsibility for...
1/20/18 - Novartis looks to next decade with Biocon biosimilar pact [Algeria Press Service]
The agreement announced this week will see Novartis subsidiary Sandoz share the development and production of an undisclosed number of third wave biosimilar candidates with Indian biomanufacturer Biocon. The biosimilar assets that are part of this agreement complement our existing portfolio in immunology and oncology, Sandoz spokesperson Chris...
1/20/18 - Remsima push Celltrions net profit up 82.1% in 2017 [Syrian Arab News Agency]
Celltrion, a Korean biopharmaceutical firm, said Friday that its net profits soared 82.1 percent in 2017 from a year earlier on robust sales of its biosimilar drug Remsima overseas. Celltrion said its operating profit more than doubled to 517 billion won in 2017 from 253 billion won a year earlier. Celltrion also began selling another biosimilar dr
1/20/18 - SOHM, Inc., Executes Non-Toxic Funding Commitment with Institutional Investor for Expansion of Core Business to Adopt Blockchain Technologies [Gulf Daily News (Bahrain)]
-SOHM, Inc. a globally-known generic pharmaceutical manufacturer, announces today that it has signed a binding Letter of Intent with a Canadian Institutional Investor for a sizable investment in SOHM. Management is confident that by incorporating blockchain technologies with its core business, SOHM will create a competitive advantage in the field o
1/19/18 - Amgen And Allergan's MVASI Gets EU Approval To Treat Certain Types Of Cancer
THOUSAND OAKS- Amgen and Allergan plc. announced Thursday that the European Commission has granted marketing authorization for MVASI. Amgen and Allergan said they are committed to developing high-quality biosimilars with a robust analytic and clinical package. Amgen noted that MVASI is the first targeted cancer biosimilar from the company's portfol
1/19/18 - Ascension, SSM partner to form generic drug company [St. Louis Post-Dispatch]
Utah- based Intermountain Healthcare is leading the collaboration that includes two St. Louis area health systems, Ascension and SSM Health, in addition to Michigan- based Trinity Health and the Department of Veterans Affairs. The generic drug company will either become an FDA- approved manufacturer or subcontract the work. One example of a pricey
1/19/18 - Asia factories eyed for generic drugs [All Iraq News Agency (AIN)]
The government is planning new measures to help Japanese companies construct pharmaceutical factories in Asian countries, where labor costs are lower than in Japan, to encourage the production of more generic drugs, The Yomiuri Shimbun has learned. The Headquarters for Healthcare and Medical Strategy Promotion chaired by Prime Minister Shinzo Abe i
1/19/18 - Biosimilar 2017: Increasing Demand and Global Industry Current Scenario 2024: Biosimilar Market By Product (Recombinant Non-Glycosylated Proteins, Recombinant Peptides, Recombinant Glycosylated Proteins),Types (Human growth hormone, Erythropoietin, M
Pune, India 01/19/2018 The Global Biosimilar Market accounted to USD 3.5 billion in 2016 growing at a CAGR of 27.0% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.. Numerous regulatory authorities which i
1/19/18 - Cadila Healthcare's Dabhasa plant clears USFDA inspection [India Infoline News Service]
Cadila Healthcare reported that its Dabhasa plant has cleared a USFDA audit with zero observations. Cadila Healthcare is currently trading at Rs447.15, up by Rs11.05 or 2.53% from its previous closing of Rs436.1 on the BSE. Cadila Healthcare is a fully-integrated, pharmaceutical company with strong presence in the formulations and CRAMS businesses.
1/19/18 - EC approves Amgen's biosimilar Avastin
Amgen Inc. and Allergan plc said the European Commission approved Mvasi, a biosimilar of Avastin bevacizumab. In September, FDA approved the drug as Mvasi bevacizumab-awwb for all cancer types on Avastin's U.S. label except ovarian cancer. Roche and its Genentech Inc. unit market Avastin.
1/19/18 - Healthcare organizations to form generics company
Intermountain Healthcare along with Ascension, SSM Health and Trinity Health are forming a not-for-profit generic drug company. The U.S. Department of Veterans Affairs will act as a consultant. The company will aim to become an FDA- approved manufacturer and will either manufacture generics directly or subcontract with CMOs.
1/19/18 - Hospitals start drug making company
TRENTON- Several major not-for-profit hospital groups are trying their own solution to drug shortages and high medicine prices: creating a company to make cheaper generic drugs. The plan, announced Thursday, follows years of shortages of generic injected medicines that are the workhorses of hospitals, along with some huge price hikes for once-cheap
1/19/18 - Leading U.S. Health Systems Announce Plans to Develop a Not-for-Profit Generic Drug Company [FARS News Agency]
To help patients by addressing the often unwarranted shortages and high costs of lifesaving generic medications, Intermountain Healthcare is leading a collaboration with Ascension, SSM Health and Trinity Health, in consultation with the U.S. Department of Veterans Affairs*, to form a new, not-for-profit generic drug company. The five organizations.
1/19/18 - Renflexis? Is Commercially Available from Inform Diagnostics
Inform Diagnostics, formerly Miraca Life Sciences, announced today that therapeutic drug monitoring is commercially available for Renflexis, a biosimilar of Remicade . Inform Diagnostics uses laboratory-validated ELISA technology for TDM. Headquartered in Irving, Texas, Inform Diagnostics is the largest independent anatomic pathology provider in.
1/19/18 - Reports on Biosimilars from University of Sydney Provide New Insights (The state-of-play and future of antibody therapeutics)
According to news originating from Sydney, Australia, by NewsRx correspondents, research stated, "It has been over four decades since the development of monoclonal antibodies using a hybridoma cell line was first reported. Financial support for this research came from Faculty of Pharmacy of The University of Sydney. Our news journalists obtained a
1/19/18 - Researchers at University of Leuven - KU Leuven Describe Findings in Biosimilars (Policies for biosimilar uptake in Europe: An overview)
By a News Reporter-Staff News Editor at Drug Week Current study results on Drugs and Therapies- Biosimilars have been published. According to news reporting from Leuven, Belgium, by NewsRx journalists, research stated, "Across European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergen
1/19/18 - Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
Holzkirchen- Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. Sandoz will lead commercialization in North America and the EU,.
1/19/18 - SOHM, Inc., Executes Non-Toxic Funding Commitment with Institutional Investor for Expansion of Core Business to Adopt Blockchain Technologies
SOHM, Inc. a globally-known generic pharmaceutical manufacturer, announces today that it has signed a binding Letter of Intent with a Canadian Institutional Investor for a sizable investment in SOHM. Management is confident that by incorporating blockchain technologies with its core business, SOHM will create a competitive advantage in the field
1/18/18 - Amerigen's petition leads to U.S. Zytiga patent invalidation
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical C
1/18/18 - Amneal Launches Budesonide Capsules
Amneal Pharmaceuticals has launched budesonide capsules, 3 mg, an AB-rated equivalent to Entocort EC. Annual U.S. sales of budesonide and its generic equivalents were $187 million, according to November 2017 IQVIA? market data. Budesonide is the first product launch of the new year for Amneal Pharmaceuticals.
1/18/18 - Ascension, SSM and others plan to develop generic drug company [St. Louis Post-Dispatch]
Utah- based Intermountain Healthcare is leading the collaboration that includes two St. Louis area health systems, Ascension and SSM Health, in addition to Michigan- based Trinity Health and the Department of Veterans Affairs. The company will either become an FDA- approved manufacturer or subcontract the work out. "All Americans deserve access to
Articles(s): 1 - 25 of 64     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415